OverviewSuggest Edit

Kodiak Sciences, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD.
TypePublic
Founded2009
HQZug, CH
Websitekodiak.com

Latest Updates

Employees (est.) (Mar 2019)31(+11%)
Job Openings7
Share Price (Mar 2020)$65.8 (-5%)

Key People/Management at Kodiak Sciences

John Borgeson

John Borgeson

Senior Vice President and Chief Financial Officer
Victor Perlroth

Victor Perlroth

Chairman and Chief Executive Officer, Founder
Desiree Beutelspacher

Desiree Beutelspacher

Vice President of Clinical Operations
Jason Ehrlich

Jason Ehrlich

Chief Medical Officer and Chief Development Officer
Hong Liang

Hong Liang

Senior Vice President, Discovery Medicine
Almas Qudrat

Almas Qudrat

Senior Vice President, Quality Operations
Show more

Kodiak Sciences Office Locations

Kodiak Sciences has offices in Zug and Palo Alto
Zug, CH (HQ)
Dammstrasse 19
Palo Alto, US
2631 Hanover St
Show all (2)

Kodiak Sciences Financials and Metrics

Kodiak Sciences Revenue

USD

Net income (FY, 2018)

(41.4m)

EBIT (FY, 2018)

(26.4m)

Market capitalization (5-Mar-2020)

2.9b

Closing stock price (5-Mar-2020)

65.8

Cash (31-Dec-2018)

88.3m
Kodiak Sciences's current market capitalization is $2.9 b.
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

3.1m3.5m7.6m

R&D expense

14.1m22.0m18.8m

Operating expense total

17.2m25.5m26.4m

EBIT

(17.2m)(25.5m)(26.4m)
USDFY, 2017FY, 2018

Cash

1.4m88.3m

Prepaid Expenses

200.0k2.2m

Current Assets

1.6m90.4m

PP&E

1.5m1.1m
USDFY, 2016FY, 2017FY, 2018

Net Income

(17.1m)(27.9m)(41.4m)

Depreciation and Amortization

257.0k549.0k490.0k

Accounts Payable

23.0k2.3m(2.3m)

Cash From Operating Activities

(16.0m)(17.7m)(29.0m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Kodiak Sciences Operating Metrics

Q2, 2018

Phase I Trials Products

1

Preclinical Phase Products

3
Show all operating metrics

Kodiak Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Kodiak Sciences Financing Corporation
Kodiak Sciences GmbH

Kodiak Sciences Online and Social Media Presence

Embed Graph

Kodiak Sciences News and Updates

Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

PALO ALTO, Calif., March 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the fourth...

Kodiak Sciences Announces Additional Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation, and Degeneration 2020 Meeting

PALO ALTO, Calif., Feb. 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced promising safety, efficacy and durability data from the...

Kodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock

PALO ALTO, Calif., Dec. 3, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering of 6,000,000...

Thinking about buying stock in E*TRADE, Kodiak Sciences, Micron Technology, Nio, or Wells Fargo?

NEW YORK, Dec. 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ETFC, KOD, MU, NIO, and WFC. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors

PALO ALTO, Calif., Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million. KSI-301 is Kodiak's...

Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights

PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the third...
Show more

Kodiak Sciences Blogs

"Kodiak" and "Kodiak Sciences" Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use

PALO ALTO, Calif. , March 24, 2020 /PRNewswire/ --  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that the company received full registration of their trademarks

Kodiak Sciences to Present at Upcoming Conferences

PALO ALTO, Calif. , Feb. 27, 2020 /PRNewswire/ --  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following upcoming investor

Kodiak Sciences Announces Upcoming Presentation of Additional KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2020 Meeting

PALO ALTO, Calif. , Feb. 5, 2020 /PRNewswire/ --  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that a presentation of additional clinical study data on its

Kodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif. , Jan. 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present a company overview at the J.P.

Kodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors

PALO ALTO, Calif. , Dec. 19, 2019 /PRNewswire/ --  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Taiyin Yang, Ph.D., to its board of directors.

Kodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PALO ALTO, Calif. , Dec. 6, 2019 /PRNewswire/ --  Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the closing of its previously announced underwritten public
Show more

Kodiak Sciences Frequently Asked Questions

  • When was Kodiak Sciences founded?

    Kodiak Sciences was founded in 2009.

  • Who are Kodiak Sciences key executives?

    Kodiak Sciences's key executives are John Borgeson, Victor Perlroth and Desiree Beutelspacher.

  • How many employees does Kodiak Sciences have?

    Kodiak Sciences has 31 employees.

  • Who are Kodiak Sciences competitors?

    Competitors of Kodiak Sciences include Vaxess Technologies, Cell Signaling Technology and Odonate Therapeutics.

  • Where is Kodiak Sciences headquarters?

    Kodiak Sciences headquarters is located at Dammstrasse 19, Zug.

  • Where are Kodiak Sciences offices?

    Kodiak Sciences has offices in Zug and Palo Alto.

  • How many offices does Kodiak Sciences have?

    Kodiak Sciences has 2 offices.